Program Trains Community Opinion Leaders in Principles of Pain Control

Publication
Article
Oncology NEWS InternationalOncology NEWS International Vol 5 No 10
Volume 5
Issue 10

DULUTH, Minn-Effective strategies to improve cancer pain management in the community may be elusive, but researchers from the Minnesota Cancer Pain Project, led by Thomas E. Elliott, MD, believe they are on the right track with an intervention program that combines education of community opinion leaders with community outreach programs.

DULUTH, Minn-Effective strategies to improve cancer pain managementin the community may be elusive, but researchers from the MinnesotaCancer Pain Project, led by Thomas E. Elliott, MD, believe theyare on the right track with an intervention program that combineseducation of community opinion leaders with community outreachprograms.

To evaluate the program, the researchers randomly assigned threepairs of matched communities to receive either intervention orno intervention, Project Director Karen Johnson, MPH, of the DuluthClinic, said at her Congress poster presentation.

Opinion leader educators (physicians, nurses, pharmacists, socialworkers, and clergy) from the intervention areas participatedin a 2-day minifellowship that included lectures, clinical andhospice rounds, and preceptorships; they then returned to theircommunities to set up a task force of other educators, to diffusethe message and train their peers. This strategy was reinforcedwith community outreach education programs.

The results showed positive trends in the intervention communitiestoward reduced pain prevalence and improvement in physicians'and nurses' knowledge and attitude scores, but none reached significance.

Although the quantitative data were not statistically significant,Ms. Johnson believes the qualitative data, derived from surveysof task force members, suggest that the intervention produced"a much larger shift in behaviors than could be demonstratedwith the instruments that we used."

The task force members reported that previously unavailable painassessment tools were now being used, and pain protocols werebeing instituted. "We believe this type of intervention,trying to change patient pain levels by educating the people whotreat them, should prove effective in future intervention studies,"Ms. Johnson said.

Recent Videos
Isatuximab plus VRd triplet therapy did not significantly increase toxicity in patients with transplant-ineligible multiple myeloma in the IMROZ trial.
Isatuximab quadruplet therapy for patients with multiple myeloma prolonged progression-free survival when compared with VRd triplet therapy.
Retrospective study data show that patients with inflammatory bowel disease may not require modification of standard radiotherapy for pelvic malignancies.
Prospective trial data may help guide treatment planning for patients with inflammatory bowel disease planning to undergo radiotherapy.
Samantha Shenoy, NP, MSN, suggests that support groups may help comfort patients experiencing adverse effects negatively impacting quality of life.
Samantha Shenoy, NP, MSN, emphasized educating patients with multiple myeloma to help prepare them for potential taste alterations after talquetamab.
Related Content